title: Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute.
abstract: Active specific immunotherapy for cancer often requires the use of autologous or allogeneic tumour cells as immunizing antigen. Tumours were obtained for such a protocol. However, estimation of viable cell yield from pre-processed fresh tumour mass was difficult, and initially there did not appear to be a direct relationship between pre-processed tumour mass and viable cells obtained after processing. We therefore analysed all of 293 tumour specimens processed to attempt to discern such a relationship. Of these 137 were melanoma, 14 were sarcoma, 48 were adenocarcinoma, 59 were renal cell carcinoma and 35 were classified as other. A positive correlation was found between pre-processed tumour mass and viable cell yield, with Spearman correlation values varying from r = 0.49 (adenocarcinoma) to r = 0.84 (melanoma). For all tumours the Spearman correlation was r = 0.70 (p = 0.0001). Not surprisingly, the most frequent site of removal associated with bacterial contamination was bowel. In conclusion, this study provides useful curves for predicting viable tumour cell yield from pre-processed tumour mass of given histology.
authors.affiliation: Pittsburgh Cancer Institute, PA.
authors.forename: T F
authors.initials: TF
authors.lastname: Logan
authors.forename: W
authors.initials: W
authors.lastname: Shannon
authors.forename: J
authors.initials: J
authors.lastname: Bryant
authors.forename: P
authors.initials: P
authors.lastname: Kane
authors.forename: N
authors.initials: N
authors.lastname: Wolmark
authors.forename: M
authors.initials: M
authors.lastname: Posner
authors.forename: J M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: M S
authors.initials: MS
authors.lastname: Ernstoff
authors.forename: J W
authors.initials: JW
authors.lastname: Futrell
authors.forename: L D
authors.initials: LD
authors.lastname: Straw
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology; D000951:Antigens, Neoplasm / Q000302:isolation & purification*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology; D002452:Cell Count; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology; D008545:Melanoma / Q000276:immunology / Q000473:pathology; D009336:Necrosis; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D012509:Sarcoma / Q000276:immunology / Q000473:pathology; D014611:Vaccination; D014612:Vaccines / Q000302:isolation & purification*
chemical_list: D000951:Antigens, Neoplasm; D014612:Vaccines